These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17095581)

  • 1. Anti-CD20 antibody treatment in refractory Class IV lupus nephritis.
    Carroll RP; Brown F; Kerr PG
    Nephrol Dial Transplant; 2007 Jan; 22(1):291-3. PubMed ID: 17095581
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatments for systemic diseases].
    Bader-Meunier B; Willems M
    Arch Pediatr; 2006 Jun; 13(6):596-8. PubMed ID: 16690273
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement.
    Saito K; Nawata M; Nakayamada S; Tokunaga M; Tsukada J; Tanaka Y
    Lupus; 2003; 12(10):798-800. PubMed ID: 14596432
    [No Abstract]   [Full Text] [Related]  

  • 4. The treatment of lupus nephritis.
    D'Cruz DP; Hughes GR
    BMJ; 2005 Feb; 330(7488):377-8. PubMed ID: 15718519
    [No Abstract]   [Full Text] [Related]  

  • 5. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.
    van Vollenhoven RF; Gunnarsson I; Welin-Henriksson E; Sundelin B; Osterborg A; Jacobson SH; Klareskog L
    Scand J Rheumatol; 2004; 33(6):423-7. PubMed ID: 15794203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].
    Takasaki Y
    Nihon Jinzo Gakkai Shi; 2012; 54(5):598-602. PubMed ID: 22991839
    [No Abstract]   [Full Text] [Related]  

  • 7. New treatment strategies for proliferative lupus nephritis: keep children in mind!
    Ranchin B; Fargue S
    Lupus; 2007; 16(8):684-91. PubMed ID: 17711908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency.
    Rech J; Hueber AJ; Kallert S; Requadt C; Kalden JR; Schulze-Koops H
    Ann Rheum Dis; 2006 Apr; 65(4):552-3. PubMed ID: 16531554
    [No Abstract]   [Full Text] [Related]  

  • 9. Exploring new territory: considering the future.
    Schneider M
    Lupus; 2007; 16(3):221-6. PubMed ID: 17432111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: emerging treatment strategies of immune-mediated glomerular disease.
    Kattah AG; Fervenza FC
    Expert Rev Clin Immunol; 2012 Jul; 8(5):413-21. PubMed ID: 22882216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of refractory lupus nephritis with a protocol including rituximab.
    Fra GP; Avanzi GC; Bartoli E
    Lupus; 2003; 12(10):783-7. PubMed ID: 14596429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of stiff person syndrome with rituximab.
    Baker MR; Das M; Isaacs J; Fawcett PR; Bates D
    J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):999-1001. PubMed ID: 15965211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The persistent challenge of lupus nephritis.
    Valesini G; Conti F
    Clin Rev Allergy Immunol; 2011 Jun; 40(3):135-7. PubMed ID: 20811786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 15. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine.
    Fu YF; Liu GL
    Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
    Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
    Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.
    Arce-Salinas CA; Rodríguez-García F; Gómez-Vargas JI
    Rheumatol Int; 2012 May; 32(5):1245-9. PubMed ID: 21258801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-based phase II trial of PCR for CLL/SLL patients.
    Kay NE; Shanafelt TD; Byrd JC; Grever MR
    Cancer Biother Radiopharm; 2007 Oct; 22(5):713-4; author reply 715-7. PubMed ID: 17979574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.